Vincerx Pharma, Inc. Common Stock
VINC
VINC was delisted on the 22nd of April, 2025.
34 hedge funds and large institutions have $10.8M invested in Vincerx Pharma, Inc. Common Stock in 2023 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 5 increasing their positions, 11 reducing their positions, and 4 closing their positions.
3% less funds holding
Funds holding: 35 → 34 (-1)
25% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 4
31% less capital invested
Capital invested by funds: $15.7M → $10.8M (-$4.87M)
55% less repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
+$1.41M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$38.8K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$16.6K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$16.3K |
| 5 |
SRC
Sage Rhino Capital
Menlo Park,
California
|
+$16K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AAA
Affinity Asset Advisors
New York
|
-$1.94M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$477K |
| 3 |
SSA
Schonfeld Strategic Advisors
New York
|
-$473K |
| 4 |
BBA
Baker Bros. Advisors
New York
|
-$293K |
| 5 |
LP
LMR Partners
London,
United Kingdom
|
-$47.4K |
VINC Hedge Fund Activity: Q3 2023 in Review
34 of the 6,302 institutional investors tracked by Wall St. Rank reported a position in Vincerx Pharma, Inc. Common Stock (VINC) for Q3 2023, worth a combined $10.8M — down 31% from $15.7M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of VINC and 3 opened new positions — a net loss of 1 holder — while 11 trimmed existing stakes and 5 added.
The largest buyer was Bank of America, adding an estimated $1.41M. The largest seller was Affinity Asset Advisors, exiting entirely with an estimated $1.94M sold.
- 34 institutional investors held Vincerx Pharma, Inc. Common Stock (VINC) as of Q3 2023, down from 35 in Q2 2023.
- Funds reported $10.8M of Vincerx Pharma, Inc. Common Stock stock for Q3 2023, down 31% quarter-over-quarter.
- 3 funds opened new Vincerx Pharma, Inc. Common Stock positions in Q3 2023 and 4 closed out, a net change of -1 holder.
- The largest Vincerx Pharma, Inc. Common Stock buyer in Q3 2023 was Bank of America, an estimated $1.41M added.
- The largest Vincerx Pharma, Inc. Common Stock seller in Q3 2023 was Affinity Asset Advisors, an estimated $1.94M sold.
Based on aggregated 13F filings for Q3 2023.